What's known? (70 words)
Rivastigmine is approved for the symptomatic treatment of persons with mild-to-moderate AD and PDD and has recently been approved in patch formulation for treatment of the same groups in the USA. Rivastigmine patch provides similar efficacy to the highest dose of rivastigmine capsule (12 mg/day) but with a superior tolerability profile. A sub-study of the IDEAL trial
showed that the majority of caregivers preferred patches to capsules for drug delivery.
What's new? (70 words)
This study investigated the safety and tolerability of the rivastigmine patch in persons with AD in an open-label setting. To complement findings from controlled clinical trials, this study was designed to mimic as closely as possible under the conditions of a clinical trial the situation in real life. The proportion of patients able to reach and maintain the maximum dose with patch exceeded previous demonstrations with an equivalent oral dose. 
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most frequent form of senile dementia (1) . The classic clinical features of AD include impairment of cognition and memory, language deterioration, decreased ability to perform activities of daily living, motor and sensory abnormalities and gait disturbances (2) .
The cholinesterase inhibitors galantamine, donepezil and rivastigmine form the mainstay of treatment for persons with mild-to-moderate AD (3, 4) . Rivastigmine is approved for the symptomatic treatment of persons with mild-to-moderate AD and Parkinson's disease dementia (PDD) and has recently been approved in patch formulation for treatment of the same groups in the USA. In 2007, a six-month, double-blind, randomized, placebo-controlled study (IDEAL; ENA713D2320) demonstrated the 9.5 mg/24 h rivastigmine patch to provide similar efficacy to the highest dose of rivastigmine capsule (12 mg/day) but with a superior tolerability profile (5) . In addition, the caregiver preference sub-study of the IDEAL trial showed that 72% of caregivers preferred patches to capsules for drug delivery (6) .
There is an increasing awareness of the importance of reaching and maintaining an optimal therapeutic dose of cholinesterase inhibitor (7). However, non-compliance with AD therapies is a wide-spread problem and is often a barrier to effective therapy (8) . It is hoped that the favourable tolerability profile and convenience of use of the rivastigmine patch could translate not only to increased compliance with AD therapies, but also to a greater proportion of patients reaching and maintaining an efficacious dose. The objective of this study was to investigate the safety and tolerability of the 9.5 mg/24 h rivastigmine patch in patients with probable AD in an open-label setting. We aimed to establish the proportion of patients who reached and maintained the target rivastigmine patch dose of 9.5 mg/24 h for at least 8 weeks compared with the proportion observed to reach the target 12 mg/day capsule dose in previous trials of rivastigmine oral applications (5, 9, 10) . Patient compliance and caregiver preference and satisfaction with the patch in this open-label setting were also evaluated. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were at high risk of drug-drug interactions, patients treated with other cholinesterase inhibitors or memantine that had cognitive, behavioural or functional worsening, or patients that did not reach the 12 mg/day rivastigmine capsule dose due to tolerability issues. All patients were cooperative, willing to complete all aspects of the study, and capable of doing so, either alone or with the aid of a responsible caregiver. In instances where patients were living in the community alone, they were required to have contact with a responsible caregiver on a daily basis to oversee treatment.
Exclusion criteria included the patient not being treated according to the product monograph for rivastigmine capsules, being involved in a clinical trial, or having a current diagnosis of an active skin lesion or disorder that would prevent accurate assessment of adhesion and potential skin irritation of the rivastigmine patch. Other exclusion criteria included a history or presence of any contraindication for the application of the study drug, use of other investigational drugs at the time of enrolment or within 30 days (or 5 half-lives) of enrolment, history of malignancy within the past 5 years, or history of hypersensitivity to any of the study drugs or to drugs with similar chemical structures.
Patients were recruited from 32 centres in Germany. The study was designed to mimic as closely as possible under the conditions of a clinical trial the situation in real life. Thus no placebo or other control group was selected and physicians were not blinded to the medication of the patient. In addition physicians were able to adjust the dosage as needed within the study.
The clinical study was designed, implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations Study drug dose adjustments and interruptions were permitted. If tolerability problems arose, the patch was removed, the dose was skipped and tolerability was reassessed following the skipped dose. If tolerability problems improved (≤ 3 days missed dose) treatment could be restarted at the same dose level. If tolerability was still an issue, and the patient had been treated with the 4.6 mg/24 h patch, the patient was considered for withdrawal from the study. If the patient had been treated with 9.5 mg/24 h patch, treatment could be re-started at the lower dose level. If tolerability was still an issue, further attempts to increase the dose upward were at the investigator's discretion. If a patient had not reached his/her target dose level during the titration period, but later had resolution of tolerability problems, the investigator could perform the dose increase during the maintenance period. Dose level decreases required for tolerability problems were allowed at any time during the maintenance period.
Outcomes
The primary outcome of this study was the proportion of patients treated with 9. Safety was monitored at all visits and assessments were based mainly on the frequency of adverse events (AEs). AEs were coded by primary system organ class and preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA). An AE related to study drug was defined as one considered to have a suspected relationship with the study drug.
Sample size and statistics
Based on the results of earlier clinical trials, (5) The safety variables were presented using summary statistics. All safety analyses were performed on the safety population, defined as all patients that received at least one dose of study drug and had at least one post-baseline safety assessment. AEs were summarized by the number and percentage of patients in each primary system organ class and preferred term. For summaries by severity of event, the most severe occurrence for a particular preferred term was used for a given patient. Multiple occurrences of the same AE or serious AE (SAE) in the same patient were counted only once, using the worst severity and drug relationship. Table 1 .
Primary objective

Compliance
Within the ITT population, 135/182 patients (adherence rate 74.2%; 95% CI 67.8-80.5%) were treated for at least 8 weeks with the 9.5 mg/24 h rivastigmine patch and completed the study (p < 0.0001). There were 147/182 patients (adherence rate 80.8%; 95% CI 75.0-86.5%) treated for at least 8 weeks with the 9.5 mg/24 h rivastigmine patch regardless of whether they completed the study (p < 0.0001).
Secondary objectives
Safety and tolerability
The number and percentage of patients experiencing AEs by system organ class (safety population) are summarized in Table 2 . Only gastrointestinal disorders, psychiatric disorders and skin and subcutaneous tissue disorders were seen in more than 10% of patients. The most common AEs were nausea (10.1% of patients), erythema (8.7% of patients), pruritus (8.2% of patients), vomiting (7.2% of patients), diarrhoea and agitation (both 4.3% of patients). Similarly, the most common AEs with a suspected relation to the study drug were erythema (8.2% of patients), nausea (7.7% of patients), pruritus (7.2% of patients) and vomiting (4.8% of patients).
Within the psychiatric disorders, agitation occurred in 4.3%, anxiety in 1%, depression in 1.4%
and hallucination in 0.5% of patients. There were 39 patients (18.8%) with AEs that led to permanent discontinuation of the study (serious in 6 patients). Consistent with the known safety profile of the rivastigmine patch, the most common AEs leading to discontinuation were skin and subcutaneous tissue disorders (7.2% of patients), psychiatric disorders (4.8% of patients), nervous system disorders (4.3% of patients), and gastrointestinal disorders (4.3% of patients). Three SAEs were associated with the study drug. There was one death during the study period, but the participant died of natural causes and a relationship with the study drug was not suspected.
Cognitive and global outcomes
The change from baseline at Week 24 on cognitive and global outcomes outcome scores (ITT population) are summarized in Table 3 (Table 3 ). The most frequent AEs were diarrhoea, nausea, vomiting, erythema and pruritus. Psychiatric disorders, gastrointestinal disorders, and skin and subcutaneous tissue disorders were the most common AEs by system organ class while receiving treatment, each occurring in more than considered to be an optimal therapeutic dose and to stay on treatment long-term (7).
The favourable tolerability, safety and efficacy profile of the rivastigmine patch may not only allow access to therapeutic doses of cholinesterase inhibitor, but may also increase treatment compliance among persons with AD and their caregivers. Non-compliance with AD therapies is a wide-spread problem and is often a barrier to effective therapy (8, 16, 17) . However, patients who continue on rivastigmine treatment for up to 5 years have shown sustained and significant benefits over model-based untreated patients (18) . A recent database analysis of a large US 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 health plan determined that only 58% of AD patients stayed on oral treatment for at least a year and concluded that educating caregivers and physicians on the importance of medication compliance is an important intervention to potentially improve patient outcomes (19) . The favourable risk-benefit profile of rivastigmine patch may provide a realistic way to increase treatment compliance with AD therapy. Approaches that improve treatment compliance may provide better long-term outcomes for patients with AD, and also offer a better quality of life to caregivers.
The strengths of our study being open-label and a real-life observational study also provide some limitations; the information it offers in terms of efficacy and tolerability of rivastigmine patch is minimal in comparison to the data from the pivotal study (5) . There was no placebo or parallel control group meaning that Week 24 changes in effectiveness in the absence of rivastigmine are unknown. In addition, physicians were not blinded to study treatment and physicians were able to adjust the dosage freely as needed within the study. The 74.5%
completion rate may also limit interpretation of the results, but while this discontinuation rate is slightly higher than that reported in the IDEAL study with rivastigmine patch and capsules, (5) it is consistent with or lower than those reported in other clinical trials with cholinesterase inhibitors (9, 10, 20) . It is also appreciated that the proportion of patients able to reach and maintain the highest available dose of rivastigmine in this open-label setting may be due to factors additional to the mode of delivery, such as the presence of comorbidities, the level of care of therapeutic teams and the degree of engagement of relatives or caregivers. Longer-term follow-up is required to elucidate the full impact of the rivastigmine patch on treatment adherence, compliance and ability to permit access to optimal therapeutic doses of rivastigmine.
Our study demonstrates that transdermal delivery may allow a greater proportion of patients to reach and maintain therapeutic target doses of rivastigmine compared with oral rivastigmine.
With increasing recognition of treatment compliance and the benefits of reaching a therapeutic dose and staying on treatment long term, the rivastigmine patch should be considered a viable option for the first-line treatment of patients with mild-to-moderately severe AD. 
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